Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO 2017 Congress; abstract LBA2_PR.
Leendert Trouw benoemd tot hoogleraar Complementbiologie en -therapie
feb 2023 | Immuuntherapie, RA, Tuberculose